Surgery Partners, Inc. (SGRY)

From a risk management standpoint, the slowdown in SGRY's MandA pace is the headline worth tracking. While management reaffirmed confidence in its strategy during the second quarter, they acknowledged falling short of the $200.0 million average annual MandA investment target for 2026. This pivot toward portfolio optimization, divestitures, and a planned $795 million hospital sale shows they are tightening focus on short-stay surgical facilities, but execution risk remains elevated given current cost pressures.

Looking at the Q2 2026 numbers on our desk, SGRY posted revenues of $848.9 million, up from $826.2 million last year, driven by a 5.0% increase in days adjusted same-facility revenues. However, the net loss of $15.0 million and rising cost of revenues—reaching 77.6% of sales compared to 76.3% previously—raise real concerns about margin compression from provider taxes and high-acuity procedure expenses. Management is maintaining its 2026 revenue guidance between $3.35 billion and $3.45 billion, but the market is clearly punishing the bottom-line performance.

Evaluating the operational footprint in our clinic network, SGRY continues to operate 178 surgical facilities across 30 states. Same-facility case volumes grew modestly by 0.3%, accompanied by a 4.8% increase in revenue per case. The secular shift toward outpatient and short-stay surgical care remains intact, which explains why web traffic and alternative data signals show steady fundamental interest, even as alternative rating models score the stock as a hold around $13.95.

On our equity trading desk, sentiment around SGRY is heavily divided. On one hand, reaffirming the full-year revenue outlook in July 2026 gives institutional investors a reliable anchor amid choppy short-term share price action. On the other hand, the persistent net loss attributable to common shareholders and the slower-than-planned deployment of capital into new acquisitions complicate the long-term growth narrative for pure-play ASC bulls.

Looking at alternative data metrics tracked over the past 90 days, SGRY shows an AI score of 53/100, landing it firmly in 'Hold' territory. While monthly web visits climbed 31.4% to 19K and employment indicators remain stable at 75/100, the fundamental score sits at 55/100. We are advising clients to watch how management executes its portfolio rationalization and hospital divestitures before taking aggressive long positions.